• linkedin
  • Increase Font
  • Sharebar

    AUA '17 puts emphasis squarely on 'value'

    New era of value-based care permeates policy, clinical presentations


    Prostate Cancer Markers/Surveillance

    Stacy Loeb, MD, MScDr. LoebDevelopments in markers for prostate cancer and active surveillance for men with low-risk disease continue to be major topics at the AUA annual meeting, says Stacy Loeb MD, MSc, assistant professor of urology and population health at New York University Langone and the Manhattan VA, New York.

    “Several new serum and urine markers are being presented for use in prostate cancer diagnosis and prognostication. For men with prostate cancer, multiple studies look at the use of genomic tissue tests (eg, Prolaris, Oncotype Dx, and Decipher) to improve patient selection for upfront treatment versus active surveillance, or for decisions about secondary therapy,” she said.

    Other major biomarker-related themes are the utility of commercially available markers in African-American men, the incremental value of marker tests in the context of multiparametric MRI, and the role of markers in advanced disease.

    While active surveillance is now the recommended management option for most men with low-risk prostate cancer, some studies suggest that it remains underutilized in the United States, Dr. Loeb pointed out.

    “Correspondingly, several studies attempt to define potential barriers to surveillance among health care providers and patients, such as the risk of prostate biopsy complications,” she said. “For men who choose active surveillance, look out for numerous studies on the role of MRI during follow-up and what is the optimal biopsy protocol to use.”

    Specifically, Dr. Loeb pointed to these abstracts in the area of prostate cancer markers/surveillance:

    MP28-11: Impact of the 17-gene panel on active surveillance persistence in contemporary urologic practices: An interim analysis in an observational cohort

    Gregg Eure


    PD28-03: Correlation between a genomics test and adverse pathology after radical prostatectomy among active surveillance candidates

    Patrick Hurley


    MP43-03: Do prostate biopsy-associated complications influence treatment selection for patients with newly diagnosed, clinically localized prostate cancer?

    Melanie Adamsky


    MP43-20: Rates of non-definitive management for low and intermediate risk prostate cancer are similar between African Americans and Caucasians

    John Burns


    PD71-01: Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: interim results from the multicenter prospective pro-impact study

    John L. Gore


    PD28-06: Variation in the use of active surveillance for low-risk prostate cancer

    Björn Löppenberg


    PD28-07: Tracking of prior positive sites by mri/us fusion improves detection of gleason score upgrading

    Edward Chang


    PD28-09: Does MRI-fusion prostate biopsy improve risk reclassification for patients with prostate cancer on active surveillance compared to transrectal ultrasound-guided saturation biopsy

    Ahmed El Shafei

    Richard R. Kerr
    Kerr is group content director for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available